Stockscreener 앱 받기
7.42
0.93%
-0.07
시간 외 거래:
7.42
Arvinas Inc 주식(ARVN)의 최신 뉴스
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Price-Driven Insight from (ARVN) for Rule-Based Strategy - Stock Traders Daily
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas sharpens pipeline focus after first PROTAC approval, eyes key trial data - MSN
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data - MarketBeat
Arvinas joins MJFF initiatives to advance LRRK2 research - BioWorld News
Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease - marketscreener.com
Arvinas, Inc. Joins The Michael J. Fox Foundation's LITE And PPMI Programs To Advance New Therapies Targeting LRRK2 For Parkinson's Disease - marketscreener.com
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI - GlobeNewswire
Arvinas joins Michael J. Fox effort to develop new Parkinson's therapies - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ARVN Reiterates by Stephens & Co. -- Price Target Maintained at $18 - GuruFocus
ARVN: First PROTAC degrader approved; pipeline prioritization and key milestones drive focus - TradingView
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development - TipRanks
ArvinasAnnounces Re-Prioritization Of Portfolio Following Strategic ReviewSEC Filing - TradingView
Arvinas reprioritizes pipeline, to complete ARV-806 Phase 1 data and seek out-license; cash runway into H2 2028 - TradingView
Arvinas (ARVN) refocuses ARV-806 strategy and projects cash runway into second half of 2028 - Stock Titan
(ARVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Full Transcript: Arvinas Q1 2026 Earnings Call - Benzinga
Monaco Asset Management SAM Has $833,000 Holdings in Arvinas, Inc. $ARVN - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - The Manila Times
Arvinas, Inc. to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 3, 2026 - Quiver Quantitative
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Arvinas Inc. (ARVN) Stabilizes Near Support Amid Biotech Sector CautionVolatility Skew - thelegaladvocate.com
Arvinas Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Arvinas Employees Give Back During Company-wide Impact Day - Sahm
Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - 富途牛牛
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts - Investing.com India
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas staff spend a day cooking, cleaning and crafting for patients and kids - Stock Titan
These analysts increase their forecasts on Arvinas after Q1 results - MSN
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Arvinas Holding Company (ARVN) - The Globe and Mail
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN) - Sahm
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Yahoo Finance
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
HC Wainwright Comments on Arvinas' Q2 Earnings (NASDAQ:ARVN) - MarketBeat
1.27%
1.43%
자본화:
|
볼륨(24시간):